FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b). |
|---|
| |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | |
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

| 1. Name and Addre | 1 0 | | 2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS] | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
|-----------------------------------|---|----------|---|-------------------|---|----------------|--|--|--|--|
| NUSSBAUN | <u>A SANULI</u> | | | X | Director | 10% Owner | | | | |
| | | | — | | Officer (give title | Other (specify | | | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) | | below) | below) | | | | |
| COHERUS BIO | SCIENCES | INC | 01/10/2020 | | | | | | | |
| | 1 A A A A A A A A A A A A A A A A A A A | | | | | | | | | |
| 333 TWIN DOLPHIN DRIVE, SUITE 600 | | | | _ | | | | | | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indiv Line) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) REDWOOD | | | | X | Form filed by One Reporting Person | | | | | |
| | CA 94065 | | | | Form filed by More than One Reporting | | | | | |
| CITY | | | | | Person | | | | | |
| | | | — | | | | | | | |
| (City) | (State) | (Zip) | | | | | | | | |
| | | | | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | Securities Beneficially | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|---|------|---|---|---------------|-------|------------------------------------|---|---|
| | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (1150.4) |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | | | T | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|--|---------------------------------|--|--------------------|--------------------|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | 5. Numl of Derivati Securiti Acquire (A) or Dispose of (D) (I 3, 4 and | ive ies ed ed nstr. | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | Date of Securities | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Buy) | \$17.73 | 01/10/2020 | | A | | 20,000 | | (1) | 01/10/2030 | Common Stock | 20,000 | \$0.00 | 20,000 | D | |

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

| <u>/s/ Jean-Frederic Viret, as</u> | |
|------------------------------------|------------|
| Attorney-in-Fact for Samuel R. | 01/14/2020 |
| Nussbaum, M.D. | |

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.